Slide 1: Q1FY23 Investor Presentation
Q1FY23 Investor Presentation July 2022 Classified as Restricted B I O C O N L I M I T E D 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: Biocon is a global biopharmaceutical enterprise
Biocon is a global biopharmaceutical enterprise that is led by a purpose to develop innovative solutions that provide affordable access to high quality, essential and life saving medicines for patients, payers and health systems across the world. Classified as Restricted B I O C O N L I M I T E D 3
Slide 4: The Biocon Manifesto
The Biocon Manifesto accessibility affordability • Use our science, scale and • Focus on the kind of expertise to enhance access innovation that adds the to essential drugs for condition of affordability to patients on the lowest rung accessibility of the economic ladder As a committed stakeholder o
Slide 5: The Biocon Value Creation Journey
The Biocon Value Creation Journey 1978- 2000- 2005- 2010- 2016- 2019 & 1999 2004 2009 2015 2018 Beyond An Transforming Building the Base Strategic Global Commercialized Poised for Enzymes into a Business and Alliance with Mylan Biosimilars for Global Impact Company Biopharma Expertise in for Biosimi
Slide 6: Biocon Today: Strategically poised for a strong global play
Biocon Today: Strategically poised for a strong global play Rs. 8,397 Cr | $1.1bn ~15,000 Revenue* Total Employees* ~1,300 50+ Patents* cGMP approvals from International regulatory agencies 120+ Ranked 5 Countries where Among Top 10 Global our products are Biotech Employers by available Science maga
Slide 7: Achievements
TransformAction : Transforming Sustainability at Biocon through Action PATIENT PEOPLE SOCIAL ENVIRONMENT STAKEHOLDER o 5.3M patients reached o Top 5 among global pharma & o Published Human Rights o 58% electricity came o Board Committees, policies through biosimilars biotech employer since 2012 Poli
Slide 8: Business Segments
Business Segments Classified as Restricted B I O C O N L I M I T E D 88
Slide 9: Growth Verticals: Aligned With Shifting Paradigms
Growth Verticals: Aligned With Shifting Paradigms From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally. Ensuring Expanding Pushing Partnering to access through access through scientific deliver
Slide 10: Generics: API – the building blocks
Generics : API – the building blocks BUSINESS OVERVIEW GROWTH DRIVERS ACROSS S T R AT E G I C P R I O R I T I E S Among world’s largest manufacturers of statin & immunosuppressant APIs; leadership in Fermentation • Expanding beyond • Expanding based APIs fermentation-based APIs in select (e.g. pepti
Slide 11: Generics: Forward integrating to Generic Formulations
Generics : Forward integrating to Generic Formulations BUSINESS OVERVIEW GROWTH DRIVERS ACROSS S T R AT E G I C P R I O R I T I E S Leveraging in-house API expertise to forward integrate • Expanding portfolio through and move up the value chain - Vertical integration & - In-licensing strategy Portfo
Slide 12: Generics: Q1FY23 Update
Generics: Q1FY23 Update KEY HIGHLIGHTS Q1FY23 Q1FY23 YoY growth due to continued performance in API & recently launched generic formulations, coupled with lower base last year Revenue ₹580Cr ₹486Cr +19% Launched vertically integrated formulation, Mycophenolic Acid Delayed Release tablet in the US Re
Slide 13: Biosimilars: Overview
Biosimilars : Overview Leadership in biologics R&D, manufacturing and 8 2 3 25+ commercialization built over two decades Approved Research & Manufacturing sites cGMP approvals Products1 Development sites (2 Bengaluru, 1 Malaysia) (incl. FDA & EMA) Driven by high scientific acumen with analytical and
Slide 14: Biosimilar strategy resulted in several 'firsts'
Biosimilar strategy resulted in several ‘firsts’ Achieved many firsts in the space despite the nascent biosimilars regulatory pathway, setting new benchmarks for the industry 2004 2017 2018 2021 1st company to 1st company to 1st company to 1st company to receive commercialize human receive approval
Slide 15: Growing participation in global biosimilars market
Growing participation in global biosimilars market PA R T N E R BBL ROLE BBL ECONOMICS Biosimilars co-developed and co-commercialized with R&D and manufacturing led by BBL (2009) Set of next-gen biosimilars being co-developed (2018) Independently developing several biosimilar assets (ONGOING) Acquis
Slide 16: Acquisition of Viatris' biosimilars business
Acquisition of Viatris’ biosimilars business to add financial depth and global commercial capabilities… 1 Revenue EBITDA BBL to realize full revenue and profits Financial $1.1b | $250m from all its collaboration programs Viatris Biosimilars CY23 estimate1 2 Commercialization, Supply Chain and Operat
Slide 17: Biosimilar Value Chain
…transforming into a fully-integrated global biosimilars business POST ACQUISITION OF VIATRIS’ BIOSIMILARS CURRENT BUSINESS Emerging Markets Developed Markets Global Markets PRODUCT DEVELOPMENT Biosimilar Value Chain CLINICAL TRIALS R E G U L AT O R Y M AN U FAC T U R I N G S
Slide 18: Entering adjacencies in communicable disease: antibodies and vaccines
Entering adjacencies in communicable disease: infectious disease antibodies and vaccines Key Commercial Products (COVID -19) Recent Collaborations 50,000+ lives impacted Continued portfolio expansion Classified as Restricted B I O C O N L I M I T E D 18
Slide 19: Asset-light entry into vaccines through SILS alliance
Asset-light entry into vaccines through SILS alliance BBL RIGHTS 1 Access to 100m doses of vaccines annually for ~15 years 2 Commercialization rights of the SILS portfolio for global markets 3 BBL to have committed revenue stream and related margins from H2 FY23 Alliance to commercialize SILS COVID
Slide 20: Comprehensive portfolio of biosimilars and vaccines
Comprehensive portfolio of 20 biosimilars and vaccines… B I O S I M I L A R P R O D U C T S TAT U S Therapeutic Molecule Area US Dev. Markets: ex-US MoW4 Commentary Pegfilgrastim1 Europe, CANZ - bBevacizumab: Approved in EU, Canada 1 Trastuzumab Europe, CANZ and Australia; US approval awaiting site
Slide 21: Set up to deliver sustainable growth trajectory
…set up to deliver sustainable growth trajectory BIOCON BIOLOGICS GROWTH DRIVERS Today < 2 years 2-4 years >4 years - Pegfilgrastim - Bevacizumab (US) - Aflibercept2 - Pertuzumab - Trastuzumab - Aspart (US) - Ustekinumab - Glargine 300 IU - Bevacizumab (EU) - Adalimumab (US) - Denosumab - Seven undi
Slide 22: Biosimilars: Q1 FY23 Update
Biosimilars: Q1 FY23 Update KEY HIGHLIGHTS Q1FY23 Q1FY22 Revenue growth excluding COVID-19 related sales at 46% YoY Revenue ₹977Cr ₹758Cr +29% Progress of our unpartnered biosimilars pipeline, including bUstekinumab & bDenosumab, increased R&D cost by 120% YoY Core EBITDA* Non-cash foreign currency
Slide 23: Biocon Biologics offers differentiated value proposition
Biocon Biologics offers differentiated value proposition through its state-of-the-art platform 1 Fully integrated global biosimilars company (lab to market) 2 Strong commercial presence in global markets 3 Comprehensive portfolio of insulins, mAbs and vaccines 4 Global scale biologics manufacturing
Slide 24: Novel Molecules: Pushing scientific boundaries
Novel Molecules: Pushing scientific boundaries to deliver impactful innovations Disease Area Asset Current Progress Graft-Versus-Host Disease (GVHD) • Pivotal Phase III Study initiated in Mar ’22 for use in First-Line treatment of Acute GVHD; patient dosing initiated • European Commission granted an
Slide 25: Novels: Q1 FY23 Update
Novels : Q1 FY23 Update KEY HIGHLIGHTS Equillium initiated patient dosing for the pivotal Phase III clinical study of Itolizumab in patients with aGVHD* Patient recruitment continues for the pivotal Phase 1b clinical study of Itolizumab for Lupus Nephritis Recommended dose established** at 1500 mg o
Slide 26: Research Services (Syngene): Overview
Research Services (Syngene) : Overview Offering integrated research, development & manufacturing services for small & large molecules, antibody-drug conjugates & oligonucleotides backed by best-in-class bioinformatic services World-class R&D and manufacturing infrastructure spread over 2 million squ
Slide 27: Research Services: Q1FY23 Update
Research Services: Q1FY23 Update KEY HIGHLIGHTS Q4FY22 Q4FY21 Results against a strong quarter last year due to Remdesivir sales. Excluding Remdesivir, ~30%YoY revenue growth Revenue ₹645Cr ₹595Cr +8% Signed 10-year agreement with Zoetis for commercial manufacturing of drug substance for Librela®, M
Slide 28: Financial Highlights
Financial Highlights Classified as Restricted B I O C O N L I M I T E D 28 28
Slide 29: Financial Highlights: Q1FY23
Financial Highlights: Q1FY23 Q1FY23 Q1FY22 Biosimilars +29% | Generics +19% | Revenue +23% ₹2,217Cr ₹1,808Cr Research Services +8% Core EBITDA* +25% ₹660Cr ₹530Cr Forex Loss of ₹38Cr vs Gain of ₹17Cr in Q1FY22 % margin 31% 30% Gross R&D spend at ₹223Cr vs ₹136Cr in EBITDA +9% ₹478Cr ₹437Cr Q1FY22 R&
Slide 30: Financial Highlights: FY22
Financial Highlights: FY22 FY22 FY21 Biosimilars +24% | Research Services +19% | Generics -1% Revenue +14% ₹8,397Cr ₹7,398Cr Dilution Gain in Associates of ₹30Cr vs ₹160Cr in FY21 Core EBITDA* +18% ₹2,669Cr ₹2,270Cr Mark-to-market loss on investments of ₹28Cr; Forex Gain of ₹58Cr vs loss of ₹9Cr % m